Login / Signup

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension.

Mattias ArvidssonAbdulla AhmedHabib BouzinaGöran Rådegran
Published in: ESC heart failure (2021)
Plasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi-marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Keyphrases